Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Marinus Pharma CS (MRNS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Market Trends Toward New Normal in Discovery Communications, Otonomy, Marinus Pharmaceuticals, Citizens Financial Group, Washington Prime Group, and Charles Schwab -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Discovery Communications, Inc....

CFG : 41.70 (-0.10%)
DISCK : 18.45 (+0.27%)
SCHW : 50.85 (-1.05%)
OTIC : 5.00 (-0.99%)
MRNS : 7.46 (-5.09%)
WPG : 7.09 (+1.14%)
Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc.

NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Marinus Pharmaceuticals closed up 14% higher on Thursday after SAGE Therapeutics revealed positive clinical trial data for a postpartum depression...

SAGE : 162.02 (-3.18%)
OTIC : 5.00 (-0.99%)
MRNS : 7.46 (-5.09%)
Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, Marinus Pharma, and NewLink Genetics

If you want a Stock Review on CYTX, SRNE, MRNS, or NLNK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com observes the...

SRNE : 2.33 (+3.56%)
CYTX : 0.26 (unch)
MRNS : 7.46 (-5.09%)
NLNK : 8.66 (+2.73%)
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today...

MRNS : 7.46 (-5.09%)
Today's Research Report Coverage on Biotech Stocks -- Marinus Pharma, NewLink Genetics, Akcea Therapeutics, and Amgen

If you want a Stock Review on MRNS, NLNK, AKCA, or AMGN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Friday, September 29, 2017, the NASDAQ Composite,...

AKCA : 18.95 (+2.43%)
AMGN : 177.27 (+1.06%)
MRNS : 7.46 (-5.09%)
NLNK : 8.66 (+2.73%)
Few Biotech Stocks Keep Momentum Going With Key Developments and FDA Approvals

PALM BEACH, Florida, September 26, 2017 /PRNewswire/ --

ACRX : 2.10 (unch)
BCRX : 5.13 (-1.54%)
NVAX : 1.40 (-2.10%)
MRNS : 7.46 (-5.09%)
MBRX : 1.80 (unch)
Few Biotech Stocks Keep Momentum Going With Key Developments and FDA Approvals

One attractive position with regards to the biotech industry is that there are practically always a few industry leaders on weekly basis that are achieving new milestones and accomplishing key developments...

ACRX : 2.10 (unch)
BCRX : 5.13 (-1.54%)
NVAX : 1.40 (-2.10%)
MRNS : 7.46 (-5.09%)
MBRX : 1.80 (unch)
Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward...

MRNS : 7.46 (-5.09%)
Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of...

MRNS : 7.46 (-5.09%)
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the pricing of an underwritten public offering of 9,333,334 shares of common stock for a public offering price of $3.75...

MRNS : 7.46 (-5.09%)
Marinus Pharmaceuticals Announces Public Offering of Common Stock

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is...

MRNS : 7.46 (-5.09%)
Biotechs Ramp up Clinical Trial Programs as FDA Looks at More Efficient Drug Development Programs

PALM BEACH, Florida, September 13, 2017 /PRNewswire/ --

ALDX : 6.75 (-2.88%)
TEVA : 16.53 (+2.93%)
FWP : 4.03 (-3.35%)
MRNS : 7.46 (-5.09%)
MBRX : 1.80 (unch)
Biotechs Ramp up Clinical Trial Programs as FDA Looks at More Efficient Drug Development Programs

The hope of new measures for the FDA to advance the regulatory path for drug development is forging ahead incorporating relatively swift pivotal data in seeking accelerated approvals. FDA commissioner...

ALDX : 6.75 (-2.88%)
TEVA : 16.53 (+2.93%)
FWP : 4.03 (-3.35%)
MRNS : 7.46 (-5.09%)
MBRX : 1.80 (unch)
Marinus Stock Surges on Successful Phase II Epilepsy Study

Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.

ADVM : 3.40 (-1.45%)
ACAD : 30.05 (-1.44%)
ADRO : 8.10 (-1.22%)
MRNS : 7.46 (-5.09%)
Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Teva Pharmaceutical Industries

NEW YORK, NY / ACCESSWIRE / September 12, 2017 / Marinus Pharmaceuticals and Teva both got a big boost in trading price yesterday for different reasons. Teva has finally found a new CEO and announced the...

TEVA : 16.53 (+2.93%)
MRNS : 7.46 (-5.09%)
Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone

Substantial and Durable Anti-Seizure Efficacy Shown in Patients Suffering From Severe,

MRNS : 7.46 (-5.09%)
Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and CEL-SCI Corporation

NEW YORK, NY / ACCESSWIRE / August 15, 2017 / It was a big trading day for both Marinus Pharmaceuticals and CEL-SCI Corporation on Monday. CEL-SCI shares were on the rampage to a new high after the FDA...

CVM : 1.84 (+1.66%)
MRNS : 7.46 (-5.09%)
Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Sparks Therapeutics

NEW YORK, NY / ACCESSWIRE / August 3, 2017 / Marinus Pharmaceuticals may have reported a loss in its second quarter, but traders may have been encouraged by the company's business update about a phase...

ONCE : 47.09 (-35.83%)
MRNS : 7.46 (-5.09%)
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results

Data from Studies in Rare Pediatric Epilepsies and Severe Postpartum Depression Expected in 2 Half

MRNS : 7.46 (-5.09%)
Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US

Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.

ENZ : 8.97 (+2.05%)
REGN : 380.93 (+0.04%)
MRNS : 7.46 (-5.09%)
SNY : 43.54 (+0.69%)

Van Meerten Stock Picks

5 Great Large Caps
Today I wanted to find 5 Large Caps that still had some upside potential.
ALL -0.50 , AMP -0.85 , LB +0.23 , AXP +0.27 , AKAM +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.09%) this morning are up +0.08% and European stocks are down -0.12% . Most global stocks markets moved higher ahead of central bank meetings this week from the Fed, ECB and BOE. U.S.... Read More

Chart of the Day

Chart of the Day

Viking Therapeutics (VKTX) is the Barchart Chart of the Day.  The biopharmaceutical company has a Trend Spotter, a Weighted Alpha of 206.52+ and gained 254.95% in the last year
Read More

Brugler Ag Report

Today's Commentary

Corn futures are 1 to 2 cents lower this morning, with speculative attention drawn toward the beginning of bitcoin futures trading (+26% at one point overnight!). They saw gains of 1/4 to 1 1/4 cents on Friday, but nearby Dec was 1.38% for the week. ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.